

Presidenza del Congresso

F. Ceccherini Silberstein, Roma

M. Formisano, Taranto

S. Lo Caputo, Foggia

A. Saracino, Bari

Coordinatore Abstract

A. Di Biagio, Genova

Segreteria Scientifica

C. Agrati, Roma

A. Bandera, Milano

M. Biasin, Milano

A. Calcagno, Torino

G. V. Calvino, Roma

D. Calzavara, Milano

A. Castagna, Milano

A. M. Cattelan, Padova

S. Cicalini, Roma

A. Cingolani, Roma

P. Cinque, Milano

N. Coppola, Napoli

A. Cossarizza, Modena

G. d'Ettore, Roma

N. Frattini, Milano

A. M. Geretti, Roma

C. Gervasoni, Milano

N. Gianotti, Milano

E. Girardi, Roma

G. Guaraldi, Modena

M. Lichtner, Latina

G. Madeddu, Sassari

P. Maggi, Caserta

G. C. Marchetti, Milano

P. Meli, Bergamo

S. Nozza, Milano

G. Nunnari, Messina

M. Puoti, Milano

S. Rusconi, Legnano MI

M. Santoro, Roma

L. Sarmati, Roma

V. Svicher, Roma

C. Torti, Catanzaro

O. Turriziani, Roma

M. Zazzi, Siena

Segreteria

Corsi pregressuali

D. Calzavara, Milano

M. Cascio, Milano

E. N. Cavallari, Roma

F. Di Gennaro, Bari

G. Lapadula, Monza

F. Lombardi, Roma

Comitato Annuale di Programma (CAP)

M. Andreoni, Roma

A. Antinori, Roma

G. Antonelli, Roma

A. Castagna, Milano

M. L. Cosmaro, Milano

A. d'Arminio Monforte, Milano

M. Farinella, Roma

A. Gori, Milano

F. Maggiolo, Bergamo

C. M. Mastroianni, Roma

C. Mussini, Modena

C. F. Perno, Roma

15° Congresso Nazionale ICAR

Italian Conference on AIDS and Antiviral Research

Bari, Università degli Studi Aldo Moro

14-16 Giugno 2023

Sito web: www.icar2023.it

Presidenza del Congresso:

F. Ceccherini Silberstein, Roma

M. Formisano, Taranto

S. Lo Caputo, Foggia

A. Saracino, Bari

ECM:

Congresso (14 giugno – 150-374173, 15 giugno – 150-374229, 16 giugno – 150-374237)

Promosso da SIMIT, Società Italiana di Malattie Infettive e Tropicali

e da

- **INMI**, Istituto Nazionale per le Malattie Infettive
- **ISS**, Istituto Superiore di Sanità
- **AMCLI**, Associazione Microbiologi Clinici Italiani
- **SIICA**, Società Italiana di Immunologia, Immunologia Clinica e Allergologia
- **SIMaST**, Società Interdisciplinare per lo Studio delle Malattie Sessualmente Trasmissibili
- **SITA**, Società italiana per la Terapia Antinfettiva
- **SIV-ISV**, Società Italiana di Virologia - Italian Society for Virology
- **ANLAIDS**, Associazione Nazionale per la lotta all'AIDS
- **ARCIGAY**, Associazione LGBT Italiana
- **ARCOBALENO Aids ODV**, Associazione ARCOBALENO Aids ODV
- **ASA Onlus**, Associazione Solidarietà AIDS Onlus
- **C.I.C.A.**, Coordinamento Italiano delle case alloggio per persone con HIV/AIDS
- **EpaC Onlus**, Associazione EpaC Onlus
- **LILA**, Lega Italiana per la lotta contro l'AIDS
- **MARIO MIELI**, Circolo di Cultura Omosessuale
- **Milano Check Point**, Associazione Milano Check Point

Provider e Segreteria Organizzativa

Effetti srl Via G.B. Giorgini 16 - 20151 Milano **Phone** +39 02 3343281 **Fax** +39 02 38002105 **icar@effetti.it** www.icar2023.it

Presidenza del Congresso

F. Ceccherini Silberstein, Roma

M. Formisano, Taranto

S. Lo Caputo, Foggia

A. Saracino, Bari

Coordinatore Abstract

A. Di Biagio, Genova

Segreteria Scientifica

C. Agrati, Roma

A. Bandera, Milano

M. Biasin, Milano

A. Calcagno, Torino

G. V. Calvino, Roma

D. Calzavara, Milano

A. Castagna, Milano

A. M. Cattelan, Padova

S. Cicalini, Roma

A. Cingolani, Roma

P. Cinque, Milano

N. Coppola, Napoli

A. Cossarizza, Modena

G. d'Ettore, Roma

N. Frattini, Milano

A. M. Geretti, Roma

C. Gervasoni, Milano

N. Gianotti, Milano

E. Girardi, Roma

G. Guaraldi, Modena

M. Lichtner, Latina

G. Madeddu, Sassari

P. Maggi, Caserta

G. C. Marchetti, Milano

P. Meli, Bergamo

S. Nozza, Milano

G. Nunnari, Messina

M. Puoti, Milano

S. Rusconi, Legnano MI

M. Santoro, Roma

L. Sarmati, Roma

V. Svicher, Roma

C. Torti, Catanzaro

O. Turriziani, Roma

M. Zazzi, Siena

Segreteria

Corsi pregressuali

D. Calzavara, Milano

M. Cascio, Milano

E. N. Cavallari, Roma

F. Di Gennaro, Bari

G. Lapadula, Monza

F. Lombardi, Roma

Comitato Annuale

di Programma (CAP)

M. Andreoni, Roma

A. Antinori, Roma

G. Antonelli, Roma

A. Castagna, Milano

M. L. Cosmaro, Milano

A. d'Arminio Monforte, Milano

M. Farinella, Roma

A. Gori, Milano

F. Maggiolo, Bergamo

C. M. Mastroianni, Roma

C. Mussini, Modena

C. F. Perno, Roma

• **NADIR**, Associazione Nadir

• **NPS Italia Onlus**, Network Persone Sieropositive

• **PLUS**, Rete persone LGBTQ+ sieropositive Aps

Razionale

ICAR (Italian Conference on AIDS and Antiviral Research), ideata nel 2009 per far convergere e discutere le migliori iniziative in campo scientifico e di ricerca medica all'interno di un'unica conferenza a cadenza annuale, è la più importante occasione di incontro scientifico del nostro paese in tema di HIV e altre infezioni virali delle infezioni batteriche o fungine nel paziente immunocompromesso. Ogni anno ICAR riunisce oltre 1.000 tra specialisti e ricercatori, personale sanitario non-medico e volontari delle Associazioni dei Pazienti.

Promosso da SIMIT (Società Italiana di Malattie Infettive e Tropicali), con il patrocinio di tutte le maggiori società scientifiche del settore, le Istituzioni, la Community delle Associazioni Pazienti, ICAR 2023 - in programma a Bari dal 14 al 16 Giugno presso l'Università degli Studi Aldo Moro - è presieduto da Francesca Ceccherini Silberstein, Michele Formisano, Sergio Lo Caputo, Annalisa Saracino, coadiuvati dalla Segreteria Scientifica e dagli Organi di Governo ICAR.

"From prevention to cure: ready for new challenges" è il claim che sostiene la 15° edizione del Congresso e caratterizzerà il programma scientifico, orientando la riflessione sulle sfide e le opportunità per la promozione della salute che il contesto di cambiamento dato dalla pandemia Covid-19 offre. Riteniamo sia il momento giusto per ragionare sull'esperienza del recente passato, per fare una valutazione sulla promozione della salute nel futuro e per far convergere e discutere le migliori iniziative in campo scientifico e di ricerca medica focalizzando l'attenzione sulla centralità della persona, sull'applicazione di un approccio multidisciplinare, su nuovi modelli organizzativi, sul rafforzamento degli interventi di sorveglianza epidemiologica e di prevenzione di HIV ma anche di altre malattie infettive.

Nelle tre giornate congressuali - caratterizzate da una forte interazione tra ricerca di base, translazionale, virologica, clinica e sociale e da un approccio *abstract-driven* - i temi HIV/AIDS, SARS-CoV-2, epatiti, infezioni sessualmente trasmesse, virus emergenti e/o riemergenti, vaccini, infezioni nell'immunocompromesso, restano al centro del dibattito scientifico.

La deadline per la sottomissione degli Abstract è stata fissata il **5 aprile 2023**.

Oral Communications e Oral Poster

Come ogni Congresso Nazionale abstract-driven, le Oral Communications e le Oral Poster sono state selezionate dalla Segreteria Scientifica del Congresso sulla base della qualità scientifica degli abstract pervenuti solo dopo attenta analisi e valutazione degli stessi (che avverrà entro il 16 Maggio 2023).

Le Oral Communications avranno una durata di 12 minuti cad. mentre le Oral Poster avranno una durata di 10 minuti cad.

Provider e Segreteria Organizzativa

Effetti srl Via G.B. Giorgini 16 - 20151 Milano **Phone** +39 02 3343281 **Fax** +39 02 38002105 **icar@effetti.it** www.icar2023.it

Presidenza del Congresso

F. Ceccherini Silberstein, Roma

M. Formisano, Taranto

S. Lo Caputo, Foggia

A. Saracino, Bari

Coordinatore Abstract

A. Di Biagio, Genova

Segreteria Scientifica

C. Agrati, Roma

A. Bandera, Milano

M. Biasin, Milano

A. Calcagno, Torino

G. V. Calvino, Roma

D. Calzavara, Milano

A. Castagna, Milano

A. M. Cattelan, Padova

S. Cicalini, Roma

A. Cingolani, Roma

P. Cinque, Milano

N. Coppola, Napoli

A. Cossarizza, Modena

G. d'Ettore, Roma

N. Frattini, Milano

A. M. Geretti, Roma

C. Gervasoni, Milano

N. Gianotti, Milano

E. Girardi, Roma

G. Guaraldi, Modena

M. Lichtner, Latina

G. Madeddu, Sassari

P. Maggi, Caserta

G. C. Marchetti, Milano

P. Meli, Bergamo

S. Nozza, Milano

G. Nunnari, Messina

M. Puoti, Milano

S. Rusconi, Legnano MI

M. Santoro, Roma

L. Sarmati, Roma

V. Svicher, Roma

C. Torti, Catanzaro

O. Turriziani, Roma

M. Zazzi, Siena

Segreteria

Corsi pregressuali

D. Calzavara, Milano

M. Cascio, Milano

E. N. Cavallari, Roma

F. Di Gennaro, Bari

G. Lapadula, Monza

F. Lombardi, Roma

Comitato Annuale di Programma (CAP)

M. Andreoni, Roma

A. Antinori, Roma

G. Antonelli, Roma

A. Castagna, Milano

M. L. Cosmaro, Milano

A. d'Arminio Monforte, Milano

M. Farinella, Roma

A. Gori, Milano

F. Maggiolo, Bergamo

C. M. Mastroianni, Roma

C. Mussini, Modena

C. F. Perno, Roma

Con questo spirito, forti del percorso, dell'esperienza e del riscontro acquisiti in questi anni, ci apprestiamo a mantenere intatto l'impegno verso i nostri giovani ricercatori, il personale sanitario non-medico, la Community, la società civile, attraverso le Scholarship, ICAR-CROI Awards dedicato alle giovani eccellenze della ricerca italiana, il Contest RaccontART, il Community Village.

Anche quest'anno, ICAR si rivolge ai giovani per ascoltarne la voce attraverso la nona edizione del Concorso RaccontART – il contest artistico promosso tra gli studenti delle scuole superiori – e, in tema di sanità pubblica, ICAR 2023 affronterà i problemi connessi alla cura ed alla prevenzione delle infezioni virali aprendosi alla società civile con l'offerta del Test rapido HIV, HCV e sifilide per la popolazione residente.

I destinatari dell'evento formativo sono: medico chirurgo (tutte le professioni), farmacista pubblico, biologo, tecnico sanitario di laboratorio biomedico, psicoterapista, psicologo, assistente sanitario, infermiere, educatore professionale. Sono attesi oltre 1.000 partecipanti.

Comitato Scientifico

Presidenza del Congresso

Francesca Ceccherini Silberstein, Roma

Michele Formisano, Taranto

Sergio Lo Caputo, Foggia

Annalisa Saracino, Bari

Coordinatore Abstract

Antonio Di Biagio, Genova

Segreteria Scientifica

Chiara Agrati, Roma

Alessandra Bandera, Milano

Mara Biasin, Milano

Andrea Calcagno, Torino

Giulia Valeria Calvino, Roma

Daniele Calzavara, Milano

Provider e Segreteria Organizzativa

Effetti srl Via G.B. Giorgini 16 - 20151 Milano **Phone** +39 02 3343281 **Fax** +39 02 38002105 **icar@effetti.it** www.icar2023.it



Presidenza del Congresso

F. Ceccherini Silberstein, Roma

M. Formisano, Taranto

S. Lo Caputo, Foggia

A. Saracino, Bari

Coordinatore Abstract

A. Di Biagio, Genova

Segreteria Scientifica

C. Agrati, Roma

A. Bandera, Milano

M. Biasin, Milano

A. Calcagno, Torino

G. V. Calvino, Roma

D. Calzavara, Milano

A. Castagna, Milano

A. M. Cattelan, Padova

S. Cicalini, Roma

A. Cingolani, Roma

P. Cinque, Milano

N. Coppola, Napoli

A. Cossarizza, Modena

G. d'Ettore, Roma

N. Frattini, Milano

A. M. Geretti, Roma

C. Gervasoni, Milano

N. Gianotti, Milano

E. Girardi, Roma

G. Guaraldi, Modena

M. Lichtner, Latina

G. Madeddu, Sassari

P. Maggi, Caserta

G. C. Marchetti, Milano

P. Meli, Bergamo

S. Nozza, Milano

G. Nunnari, Messina

M. Puoti, Milano

S. Rusconi, Legnano MI

M. Santoro, Roma

L. Sarmati, Roma

V. Svicher, Roma

C. Torti, Catanzaro

O. Turriziani, Roma

M. Zazzi, Siena

Segreteria

Corsi pregressuali

D. Calzavara, Milano

M. Cascio, Milano

E. N. Cavallari, Roma

F. Di Gennaro, Bari

G. Lapadula, Monza

F. Lombardi, Roma

**Comitato Annuale
di Programma (CAP)**

M. Andreoni, Roma

A. Antinori, Roma

G. Antonelli, Roma

A. Castagna, Milano

M. L. Cosmaro, Milano

A. d'Arminio Monforte, Milano

M. Farinella, Roma

A. Gori, Milano

F. Maggiolo, Bergamo

C. M. Mastroianni, Roma

C. Mussini, Modena

C. F. Perno, Roma

Antonella Castagna, Milano

Anna Maria Cattelan, Padova

Stefania Cicalini, Roma

Antonella Cingolani, Roma

Paola Cinque, Milano

Nicola Coppola, Napoli

Andrea Cossarizza, Modena

Gabriella d'Ettore, Roma

Nicoletta Frattini, Milano

Anna Maria Geretti, Roma

Cristina Gervasoni, Milano

Nicola Gianotti, Milano

Enrico Girardi, Roma

Giovanni Guaraldi, Modena

Miriam Lichtner, Latina

Giordano Madeddu, Sassari

Paolo Maggi, Caserta

Giulia Carla Marchetti, Milano

Paolo Meli, Bergamo

Silvia Nozza, Milano

Giuseppe Nunnari, Messina

Massimo Puoti, Milano

Stefano Rusconi, Legnano MI

Maria Santoro, Roma

Loredana Sarmati, Roma

Valentina Svicher, Roma

Carlo Torti, Catanzaro

Ombretta Turriziani, Roma

Maurizio Zazzi, Siena

Segreteria Corsi pregressuali

Daniele Calzavara, Milano

Mario Cascio, Milano

Eugenio Nelson Cavallari, Roma

Francesco Di Gennaro, Bari

Giuseppe Lapadula, Monza

Francesca Lombardi, Roma

Presidenza del Congresso

F. Ceccherini Silberstein, Roma

M. Formisano, Taranto

S. Lo Caputo, Foggia

A. Saracino, Bari

Coordinatore Abstract

A. Di Biagio, Genova

Segreteria Scientifica

C. Agrati, Roma

A. Bandera, Milano

M. Biasin, Milano

A. Calcagno, Torino

G. V. Calvino, Roma

D. Calzavara, Milano

A. Castagna, Milano

A. M. Cattelan, Padova

S. Cicalini, Roma

A. Cingolani, Roma

P. Cinque, Milano

N. Coppola, Napoli

A. Cossarizza, Modena

G. d'Ettore, Roma

N. Frattini, Milano

A. M. Geretti, Roma

C. Gervasoni, Milano

N. Gianotti, Milano

E. Girardi, Roma

G. Guaraldi, Modena

M. Lichtner, Latina

G. Madeddu, Sassari

P. Maggi, Caserta

G. C. Marchetti, Milano

P. Meli, Bergamo

S. Nozza, Milano

G. Nunnari, Messina

M. Puoti, Milano

S. Rusconi, Legnano MI

M. Santoro, Roma

L. Sarmati, Roma

V. Svicher, Roma

C. Torti, Catanzaro

O. Turriziani, Roma

M. Zazzi, Siena

Segreteria

Corsi pregressuali

D. Calzavara, Milano

M. Cascio, Milano

E. N. Cavallari, Roma

F. Di Gennaro, Bari

G. Lapadula, Monza

F. Lombardi, Roma

**Comitato Annuale
di Programma (CAP)**

M. Andreoni, Roma

A. Antinori, Roma

G. Antonelli, Roma

A. Castagna, Milano

M. L. Cosmaro, Milano

A. d'Arminio Monforte, Milano

M. Farinella, Roma

A. Gori, Milano

F. Maggiolo, Bergamo

C. M. Mastroianni, Roma

C. Mussini, Modena

C. F. Perno, Roma

Comitato Annuale di Programma (CAP)

Massimo Andreoni, Roma

Andrea Antinori, Roma

Guido Antonelli, Roma

Antonella Castagna, Milano

Maria Luisa Cosmaro, Milano

Antonella d'Arminio Monforte, Milano

Massimo Farinella, Roma

Andrea Gori, Milano

Franco Maggiolo, Bergamo

Claudio Maria Mastroianni, Roma

Cristina Mussini, Modena

Carlo Federico Perno, Roma

Provider e Segreteria Organizzativa

Effetti Srl – 20151 Milano

Via G. B. Giorgini, 16

e-mail: ICAR@effetti.it

<https://www.icar2023.it>

#ICAR2023

Provider e Segreteria Organizzativa

Effetti srl Via G.B. Giorgini 16 - 20151 Milano **Phone** +39 02 3343281 **Fax** +39 02 38002105 **icar@effetti.it** www.icar2023.it



mercoledì, 14 giugno 2023

Aula 4

15 : 00 - 17 : 30

>>> Pre-Conference advanced course

HIV infection in the migrant and refugee population

There were around 281 million international migrants in the world in 2021, which equates to 3.6 per cent of the global population. Migrant populations are more likely to suffer from poor health in general and HIV infection in particular. This is due to the epidemiological burden in the country of origin, as well as the vulnerability conditions during travel and the poor living conditions once in Europe, which expose them to every vulnerability. In addition, as with other people living with HIV/AIDS, migrants who are HIV-positive are subject to stigmatization and discrimination, and therefore, they hide their HIV status as long as possible, thus making support services unavailable to them. Most migrant populations live in a legal vacuum, with no stay or work permit in the host country, making frequently this an element of non-access to health services.

The aim of this course is to deepen our understanding of the migration phenomenon and HIV pathology by highlighting epidemiological data, good practises of public and private entities, sharing difficulties, and approaching the problem with possible, applicable, and sustainable solutions.

Chairs: Anna Caraglia (Roma), Mario Cascio (Milano)

15.00 - 15.20	Migrant and refugees in Italy: current scenarios	Davide Mosca, Londra
15.20 - 15.40	HIV infection in migrant population - Learning from each other	Carlo Torti, Catanzaro
15.40 - 16.00	NGOs as a first response for migrant integration and approach to the health system	Laura Amelia Rachele Rancilio, Roma
16.00 - 16.20	Public health engagement of migrants: the role of Hospital and University	Francesco Di Gennaro, Bari
16.20 - 17.30	Round table	Discussants: Francesco Di Gennaro, Bari Davide Mosca, Londra Laura Amelia Rancilio, Roma Carlo Torti, Catanzaro



mercoledì, 14 giugno 2023

Aula 1

15 : 00 - 17 : 30

>>> Pre-Conference advanced course

Current epidemiology and future perspectives on the prevention of STIs and HPV related anal cancer

Sexually Transmitted Infections (STIs) represent a concern for sexually active individuals. If undiagnosed, STIs can eventually cause serious complications. Immunization and pharmacological prophylaxis are emerging, as adjunct to periodic screening of asymptomatic people, as new strategies for approaching STIs in addition to treatment once the infection is established.

A thorough overview of the current state of the art will be offered to participants.

The dynamic of HPV transmission and the pathogenesis of this infection differs from the other STIs. The relevance of anal HPV infection and HPV related anal cancer among MSM and PLWH is emerging. The ANCHOR study represents a milestone in this field and its publication in June 2022 opened the way to the definition of the first screening guidelines for the prevention of this neoplasm, with particular attention to PLWH. A review of current literature on anal HPV infection and anal cancer risk among several key populations and a focus on these novel screening guidelines will be offered to participants.

Chairs: Daniele Calzavara (Milano), Eugenio Nelson Cavallari (Roma)

15.00 - 15.10	Evaluation of participants' knowledge on the course topics through a live on-line questionnaire (APP)	Daniele Calzavara, Milano Eugenio Nelson Cavallari, Roma
15.10 - 15.30	New insights on vaccines to prevent STIs	Davide Moschese, Milano
15.30 - 15.50	New insights on pharmacological approaches to prevent STIs	Serena Venturelli, Bergamo
15.50 - 16.15	Discussion	
16.15 - 16.35	HPV and anal cancer risk among MSM and PLWH	Roberto Paolo Iachetta, Sassuolo MO
16.35 - 16.55	New screening guidelines for the prevention of HPV related anal cancer in MSM	Marco Ridolfi, Roma
16.55 - 17.20	Discussion	
17.20 - 17.30	Revaluation of participants' knowledge on the course topics through a live on-line questionnaire (APP)	Daniele Calzavara, Milano Eugenio Nelson Cavallari, Roma



mercoledì, 14 giugno 2023

Aula 4

15 : 00 - 17 : 30

>>> Pre-Conference advanced course

HIV infection in the migrant and refugee population

There were around 281 million international migrants in the world in 2021, which equates to 3.6 per cent of the global population. Migrant populations are more likely to suffer from poor health in general and HIV infection in particular. This is due to the epidemiological burden in the country of origin, as well as the vulnerability conditions during travel and the poor living conditions once in Europe, which expose them to every vulnerability. In addition, as with other people living with HIV/AIDS, migrants who are HIV-positive are subject to stigmatization and discrimination, and therefore, they hide their HIV status as long as possible, thus making support services unavailable to them. Most migrant populations live in a legal vacuum, with no stay or work permit in the host country, making frequently this an element of non-access to health services.

The aim of this course is to deepen our understanding of the migration phenomenon and HIV pathology by highlighting epidemiological data, good practises of public and private entities, sharing difficulties, and approaching the problem with possible, applicable, and sustainable solutions.

Chairs: Anna Caraglia (Roma), Mario Cascio (Milano)

15.00 - 15.20	Migrant and refugees in Italy: current scenarios	Davide Mosca, Londra
15.20 - 15.40	HIV infection in migrant population - Learning from each other	Carlo Torti, Catanzaro
15.40 - 16.00	NGOs as a first response for migrant integration and approach to the health system	Laura Amelia Rachele Rancilio, Roma
16.00 - 16.20	Public health engagement of migrants: the role of Hospital and University	Francesco Di Gennaro, Bari
16.20 - 17.30	Round table	Discussants: Francesco Di Gennaro, Bari Davide Mosca, Londra Laura Amelia Rancilio, Roma Carlo Torti, Catanzaro



mercoledì, 14 giugno 2023

15:00 - 17:30

Auditorium Aldo Moro

>>> Special Session

RaccontART Contest Awards: incontro con le scuole finaliste e premiazione

Giunto alla nona edizione e destinato agli studenti degli Istituti Scolastici Superiori, il Contest artistico RaccontART rappresenta un'occasione unica e preziosa di formazione e informazione in tema di HIV, Infezioni Sessualmente Trasmissibili e Covid-19. Questa sessione è dedicata alla presentazione delle Opere finaliste in concorso, selezionate dalle Giurie Artistica e Tecnico-Scientifica. Al termine della Sessione, verranno premiati i primi tre classificati.

Chairs: Francesca Ceccherini Silberstein (Roma), Michele Formisano (Taranto), Sergio Lo Caputo (Foggia), Annalisa Saracino (Bari)

15.00 - 15.15 Benvenuto dei Presidenti ICAR 2023

*Francesca Ceccherini
 Silberstein, Roma
 Michele Formisano, Taranto
 Sergio Lo Caputo, Foggia
 Annalisa Saracino, Bari*

15.15 - 15.30 Introduzione e presentazione della Giuria Artistica e Tecnico-Scientifica

15.30 - 17.00 Presentazione delle Opere finaliste al Concorso a cura degli Istituti Scolastici

17.00 - 17.15 Premiazione primi 3 classificati

17.15 - 17.30 Conclusioni

18:00 - 19:00

Teatro Petruzzelli

>>> Satellite Symposium

Con la sponsorizzazione non condizionante di Gilead Sciences

HIV and COVID-19: where we are and where we are going

The life expectancy of people living with HIV (PLHIV) is now close to the one of HIV negative individuals. This important milestone has been achieved thanks to the continuous evolution of antiretroviral therapy (ART), by providing new antiretroviral regimens providing high efficacy, genetic barrier, forgiveness, tolerability, and convenience. However, a "tailored" approach has to satisfy also needs and expectations of PLWH, in order to guarantee them a therapeutic success for long-term. The symposium is also aimed at providing new insights on SARS-CoV-2 infection, especially in high-risk populations, such as comorbid and immunocompromised individuals. Through an interactive talk, experts will discuss on challenges and current and future innovative strategies that can fill the unmet needs of people living with HIV and SARS-CoV-2, supporting individuals to overcome treatment barriers and improve their quality of life.

Chairs: Giovanni Di Perri (Torino), Cristina Mussini (Modena)



Presidenza del Congresso:
F. Ceccherini Silberstein, M. Formisano,
S. Lo Caputo, A. Saracino

From prevention to cure: ready for new challenges

BARI 14-16 GIUGNO 2023
UNIVERSITA' DEGLI STUDI ALDO MORO



www.icar2023.it

Talk-show debate based on the following topics:

18.00 - 18.15	What we need in HIV treatment today to achieve long term success?	<i>Sergio Lo Caputo, Foggia</i>
18.15 - 18.30	What are the patients' needs in terms of adherence and forgiveness in HIV?	<i>Franco Maggiolo, Bergamo</i>
18.30 - 18.45	COVID-19 and comorbidities. What challenges we need to face?	<i>Emanuele Nicastrì, Roma</i>
18.45 - 19.00	Discussion and final consideration	<i>All</i>

19:00 - 20:30

Teatro Petruzzelli

>>> Session

ICAR 2023 Opening Session

Chairs: Francesca Ceccherini Silberstein (Roma), Michele Formisano (Taranto), Sergio Lo Caputo (Foggia), Annalisa Saracino (Bari)

19.00 - 19.20 **Introducing ICAR 2023. Chairs and Authorities' welcome addresses**

RaccontART: three winning works Awards

19.20 - 20.20 Keynote Lectures

Chairs: Antonella d'Arminio Monforte (Milano), Giuseppe Ippolito (Roma)

19.20 - 19.50 **Mauro Moroni Memorial Lecture: "Vaccine Hesitancy - A Story as Old as Vaccines Themselves"**

Caitjan Gainty, London

A historical & sociological perspective on vaccine hesitancy through the decades, starting with smallpox and progressing through various vaccines such as MMR and finally C-19. This aims to be a historical (rather than political or clinical) perspective, to be given by an historian.

Chairs: Giulia Valeria Calvino (Roma), Filippo Schloesser (Roma)



Presidenza del Congresso:
F. Ceccherini Silberstein, M. Formisano,
S. Lo Caputo, A. Saracino

From prevention to cure: ready for new challenges

BARI 14-16 GIUGNO 2023
UNIVERSITA' DEGLI STUDI ALDO MORO



www.icar2023.it

19.50 - 20.20 "Health pathways in transgender people. The denied rights of invisible people"


Michele Formisano, Taranto

Transgender people are a neglected population as their history is not known and there are few studies concerning the health of 'non-conforming' bodies. The lecture aims to provide incentives to explore these issues, both from a historical and a clinical point of view.

20.20 - 20.30 Opening Session & Closing remarks

*Francesca Ceccherini
Silberstein, Roma
Michele Formisano, Taranto
Sergio Lo Caputo, Foggia
Annalisa Saracino, Bari*

20:30 - 22:30



>>>

ICAR 2023 Welcome Reception



Presidenza del Congresso:
F. Ceccherini Silberstein, M. Formisano,
S. Lo Caputo, A. Saracino

From prevention to cure: ready for new challenges

BARI 14-16 GIUGNO 2023
UNIVERSITA' DEGLI STUDI ALDO MORO



www.icar2023.it

giovedì, 15 giugno 2023

09:00 - 10:00

Auditorium Aldo Moro

>>> Lecture

Keynote Lectures

Chairs: Guido Antonelli (Roma), Massimo Galli (Milano)

09.00 - 09.30 All you always wanted to know about clinical pharmacology but were afraid to ask

Stefano Bonora, Torino

The lecture will focus on pharmacological issues and characteristics of different antiviral treatments (HIV, hepatitis, COVID) which awareness could be useful to clinicians in the daily management of patients. Knowledge of some key principle of clinical pharmacology could help the clinicians to overcome the therapeutic pitfalls of real life setting.

09.30 - 10.00 Simplifying a complex issue: how to tailor drug resistance into clinical practice

Anna Maria Geretti, Roma

Despite great advancements in HIV treatment, new and existing antiretrovirals remain vulnerable to viral escape. Preventing and managing antiretroviral drug resistance is central to ensuring optimal outcomes over the life time of our patients. This is a continuously evolving field and new understandings have recently emerged that can have a profound impact on clinical care.



10:05 - 11:05

Auditorium Aldo Moro

>>> Symposium

Controversies in HIV clinical virology

While modern antiretroviral therapy has been progressing towards increased potency, convenience and durability, controversies in HIV virology and pharmacology remain. This symposium focuses on two specific issues, namely HIV drug resistance and low-level viremia, through an attractive clinician vs. virologist format. The incidence of HIV drug resistance has been decreasing due to expanded use of high genetic barrier drugs and lower rates of virological failure. However, a proportion of PLWH still develop or harbour drug resistance patterns which can challenge treatment options. In addition, people with controlled viremia can benefit from HIV DNA drug resistance testing and the advent of high-resolution sequencing methods have recently added a new layer of opportunities and challenges. On the other hand, how to deal with low-level viremia remains an open debate requiring an integrated view on antiretroviral pharmacology, adherence and the risk of emergent resistance.

Chairs: Annapaola Callegaro (Bergamo), Adriano Lazzarin (Milano)

**10.05 - 10.35 Round Table: Should we still care about drug resistance?
 Clinician and virologist in comparison**

*Valeria Micheli, Milano
 Stefano Rusconi, Legnano MI*

**10.35 - 11.05 Round Table: How to deal with Low level viraemia
 Clinician and biologist in comparison**

*Francesca Lombardi, Roma
 Franco Maggiolo, Bergamo*

10:05 - 11:05

Aula 6

>>> Sponsored Symposium

Simposio promozionale di GSK

Do mAbs still play a role in the early treatment of COVID-19 patients?

Even if the epidemiology of COVID-19 has a significant decline there is still a significant unmet need related to the management of fragile patients with COVID-19 that despite vaccination can not build an immune response that can stop SARS-CoV2 reducing hospitalization or death progression in particular in the Early Treatment setting. Actually, in Italy the weekly mortality rate of patients with COVID-19 is still high ranging from 200 to 250 patients. The evolution of the VOCs resulting in the actual omicron soup has increased COVID-19 immune escape to mAbs generally, dramatically reducing in vitro neutralizing efficacy of the majority of mAbs and only sotrovimab maintain a moderate fold reduction in vitro and vivo that can be compensated di pharmacodynamic (effector functions) and pharmacokinetic properties such as blood concentration and pulmonary system persistency. In addition, recent studies have shown that people who are immunocompromised may inadvertently play a role in spurring the mutations of the virus that create new variants. This is because some immunocompromised individuals remain at risk of getting COVID-19 despite vaccination, experience more severe disease, are susceptible to being chronically infected and remain contagious for longer if they become infected and considering that immunocompromised individuals represent approximately 2% of the overall population, this aspect should be carefully considered. So the question is the title of this Symposia "Do mAbs still play a role in the ET of COVID-19 patients?" and the answer is yes and in particular sotrovimab going beyond in vitro data that with an evidence and experience based approach has the most robust Real World Evidences even in the most difficult to treat patient by fulfilling the unmet clinical needs of the three fragile patients' dimensions: aging, impact of comorbid condition and immunocompromised patients illness or treatment related. The talk show format and the shoot the piano player final session are going to animate discussion with experts and attendees.

Chairs: Carlo Federico Perno (Roma), Annalisa Saracino (Bari)



Presidenza del Congresso:
F. Ceccherini Silberstein, M. Formisano,
S. Lo Caputo, A. Saracino

From prevention to cure: ready for new challenges

BARI 14-16 GIUGNO 2023
UNIVERSITA' DEGLI STUDI ALDO MORO



www.icar2023.it

10.05 - 10.20 Rational criteria for evaluating mAbs efficacy: beyond in vitro data *Carlo Federico Perno, Roma*

Talk Show:
Tailored experience based approach on at risk COVID-19 patient dimensions:

10.20 - 10.30 Aging *Giordano Madeddu, Sassari*

- o Why can aging influence immune response of COVID-19 patients?
- o How aging is correlated with COVID-19 mortality?
- o Which criteria should we use to select mAbs or AVs in this type of patients based on your clinical experience?

10.30 - 10.40 Frailty *Anna Maria Cattelan, Padova*

- o Which chronic comorbidities are more associated with higher risk of COVID-19 patients' progression?
- o How multimorbidities and related treatments can worsen clinical outcomes of COVID-19 patients?
- o Which criteria should we use to select mAbs or AVs in this type of patients based on your clinical experience?

10.40 - 10.50 Vulnerability *Valentina Mazzotta, Roma*

- o Why immunocompromised patients are more associated with higher risk of COVID-19 patients' progression?
- o Which pharmacological and surgical immunosuppressive treatments can worsen clinical outcomes of COVID-19 patients? (positivity, viral load, symptoms)
- o Which criteria should we use to select mAbs or AVs in this type of patients based on your clinical experience?

10.50 - 11.05 Shoot the Piano Player Experts "Q&A session" *Annalisa Saracino, Bari*

10:05 - 11:05

Aula 4

>>> Expert Meeting

Con la sponsorizzazione non condizionante di MSD Italia

Individualization and evolution of HIV management with the next generation of NNRTI: the future is now

One size doesn't fit all. Prevention and management of comorbidities. How does it impact your practice? Interactive discussion on cardio-metabolic disorders, DDI and polypharmacy and resistance to support PLWH with the first of the new generation of NNRTI.

Chair: Antonella Castagna (Milano)

Discussants: Benedetto Maurizio Celesia (Catania), Roberta Gagliardini (Roma), Cristina Gervasoni (Milano), Paolo Maggi (Caserta)



10:05 - 11:05

Aula 1

>>> Session

Oral Communications

10:05 - 11:05

Aula 3

>>> Session

Oral Poster

11:10 - 12:10

Auditorium Aldo Moro

>>> Sponsored Symposium

Simposio promozionale di ViiV Healthcare

HIV treatment outcomes with DTG/3TC in Naive and Experienced PLHIV

DTG/3TC has now demonstrated durable efficacy and tolerability both as a first-line regimen as well as in the setting of treatment optimization for experienced patients, at the same time reducing the number of antiretrovirals (compared to 3-4DR). In the setting of naïve patients, it is key to understand the criteria driving the treatment choice and the concerns associated with starting treatment with a 2DR such as DTG/3TC to compare them with the evidences available both from RCTs and real-world experiences. On the other hand, proactive treatment optimization and simplification in the experienced patient is becoming much more relevant as we focus on a preventive approach to improve the quality of life in the context of a lifelong therapy. Therefore, the aim of this symposium is discussing the most recent evidences available that supports the use of DTG/3TC in these settings.

Chairs: Stefano Rusconi (Legnano MI), Maria Santoro (Roma)

11.10 - 11.20 Opening: relevance of long term perspectives in current HIV care

*Stefano Rusconi, Legnano MI
 Maria Santoro, Roma*

Round table

11.20 - 11.35 Decision criteria and concerns around DTG/3TC usage in naive patients

Nicola Gianotti, Milano



11.35 - 11.50 Long-term outcomes of treatment simplification: the role of DTG/3TC *Simona Di Giambenedetto, Roma*

11.50 - 12.05 DTG/3TC and metabolic health *Nicola Squillace, Monza*

12.05 - 12.10 Closing and take home messages *Stefano Rusconi, Legnano MI
 Maria Santoro, Roma*

11:10 - 12:10

Aula 6

>>> Satellite Symposium

Con la sponsorizzazione non condizionante di Gilead Sciences

A new era of HDV treatment: relevance of HDV control in coinfecting patients

Hepatitis delta virus (HDV) is a defective agent that only infects individuals with hepatitis B virus (HBV). Around 5-10% of chronic hepatitis B patients worldwide are superinfected with HDV, which means 15-25 million people. Hepatitis delta is the most severe of all chronic viral hepatitis, leading to cirrhosis, liver cancer and/or transplantation in most patients. The only treatment available until recently was peginterferon alfa, with poor results and significant side effects. The recent approval of bulevirtide, a lipopeptide that blocks HBV/HDV entry, has revolutionized the field. Given that sexual and parenteral transmission routes are the most frequent for the acquisition of HBV and HDV, shared with HIV infection and HBV/HDV and HIV coinfection. The clinical outcome of hepatitis delta is worst in the HIV setting, with more frequent liver complications.

Chairs: Antonella d'Arminio Monforte (Milano), Teresa Santantonio (Foggia)

11.10 - 11.30 New therapeutic options for HDV: from RCT to Real world *Elisabetta Degasperi, Milano*

11.30 - 11.50 HIV-HBV-HDV coinfecting patients in ICONA Cohort: practical management recommendations *Massimo Puoti, Milano*

11.50 - 12.00 Discussion

12.00 - 12.10 The patient voice *Chiara Taibi, Roma*

11:10 - 12:10

Aula 4

>>> Session

Oral Communications



11:10 - 12:10

Aula 1

>>> Session

Oral Communications

11:10 - 12:10

Aula 3

>>> Session

Oral Poster

11:10 - 12:10

Aula 2

>>> Parallel Session

Health and prevention in transgender people

Studies carried out across a variety of different contexts have shown that transgender and gender diverse (TGD) people face significant barriers to accessing health care and health-determining resources, such as education, employment and housing. Harassment and discrimination contribute to high rates of stress and make transgender individuals significantly more likely to experience poor health outcomes (e.g., high risk for mental health morbidity, STI, cardiac disease, etc). Thus, it is urgently warranted to provide an effective and appropriate evidence-based prevention and care so as to ensure health equity for transgender people. In particular, TGD people are at high risk for HIV infection but prevention efforts targeting these people have been minimal. HIV pre-exposure prophylaxis (PrEP) is highly effective at preventing HIV, however PrEP use among TGD people remains low. In this section, an overview of the main barriers that TGD people have to face accessing healthcare services will be given and possible future strategies will be discussed.

Chair: Antonella Palmitesta (Roma)

11.10 - 11.25 **In-practice policies to promote an inclusive health care for transgender People**

Marina Pierdominici, Roma

11.25 - 11.40 **Transgender health and communication strategies: the website Infotrans.it**

Matteo Marconi, Roma



11.40 - 11.55 Sociosanitary conditions of transgender PWHIV: photography and possible inclusion tools

Luisa Brogonzoli, Milano

11.55 - 12.10 Barriers in the use HIV prophylaxis in transgender individuals

Teresa Bini, Milano

12:15 - 13:15

Auditorium Aldo Moro

>>> Symposium

The case of weight gain: is it a relevant issue in the management of PWH? PROs and CONS

Weight gain in people on antiretroviral treatment has been observed in numerous cohorts and continues to be an issue of intense debate. Indeed, several aspects are not yet clear: how weight gain is affected by specific antiretroviral treatments, pre-existing body weight or other factors, what are the underlying mechanisms, and to what extent is this a clinically relevant issue, depending on actual rate and extent and associations with metabolic disorders and other conditions. This symposium aims to weight pros and cons from ID and other specialists on whether weight gain is clinically relevant in PWH and gain knowledge towards optimal management.

Chairs: Paolo Bonfanti (Monza), Francesca Vichi (Firenze)

12.15 - 12.20 Introduction

Gabriella d'Ettorre, Roma

12.20 - 12.30 YES, weight gain is a truly relevant issue

Paolo Maggi, Caserta

12.30 - 12.40 NO, weight gain is not that much relevant afterall

Stefania Cicalini, Roma

12.40 - 12.50 Increased CV risk related to minimal to substantial weight gain: the cardiologist view

Claudio Borghi, Bologna

12.50 - 13.00 The association of weight gain with (diabetes and) metabolic alterations: the endocrinologist view

Daniele Gianfrilli, Roma

13.00 - 13.15 Round Table and conclusion

*Gabriella d'Ettorre, Roma
 Francesca Vichi, Firenze*



12:15 - 13:15

Aula 4

>>> Expert Meeting

EVERY LEFT IS LOST, LET'S VACCINATE

Some infectious diseases are preventable, and vaccination is one of the most effective and safe measure in Public Health for their primary prevention. Over time, the introduction of vaccinations has made it possible to reduce the spread of some serious and deadly diseases, or even to eliminate them. Although, paradoxically, it is precisely the success of vaccinations that creates problems in their acceptance, since the decrease in the frequency of these preventable diseases has led to a decrease in the perception of their severity. The immunocompromised patient is among the ones at greater risk of infections, and therefore vaccinations become fundamental for its management. Among vaccinations recommended for immunocompromised patients the main are against: flu, herpes zoster, pneumococcus and meningococcus. In this process, the infectious disease specialist has a central role for both the patient and the other specialists involved.

Chairs: Claudio Maria Mastroianni (Roma), Ombretta Turriziani (Roma)

Discussants: Massimo Andreoni (Roma), Michele Conversano (Taranto), Ivan Gentile (Napoli)

12:15 - 13:15

Aula 1

>>> Session

Oral Communications

12:15 - 13:15


Aula 3

>>> Session

Oral Poster



13:15 - 14:15



>>> Session

Poster viewing

13:15 - 14:15

Aula 2

>>> Session

The Italian Fast-track Cities: strengths and weaknesses of a growing movement

Since December 2018, when Milan, the first Italian city, joined the global network of Fast-track Cities Initiative, the number of participating cities has steadily increased. This movement is one of the most important innovation in the national overview of territorial actions to reach the UNAIDS 95-95-95 goal by 2030. However, this growth is characterized by light and shadow. Some cities are blocked in their first declaration of intent or have difficulties in developing necessary collaboration between public institutions and social organisations in order to achieve tangible actions. Others cities are totally changing the face of fight against HIV in their own territories. A further difficulty, but which is also a possibility, concerns the sharing of good practices and the most effective actions between Italian Fast-track Cities.

Chairs: Paolo Meli (Bergamo), Giancarlo Orofino (Torino)

13.15 - 13.25	Activities in the last year of the Italian FTCs	<i>Ilaria Mercurio, Bergamo</i>
13.25 - 13.35	The U=U campaign of the city of Turin	<i>Stefano Patrucco, Torino</i>
13.35 - 13.45	The first steps of the city of Ancona	<i>Luca Saracini, Ancona</i>
13.45 - 13.55	A project for the most vulnerable people in the city of Bergamo	<i>Davide Meli, Bergamo</i>
13.55 - 14.15	Common projects and actions are possible?	<i>FTCI delegates</i>



Presidenza del Congresso:
F. Ceccherini Silberstein, M. Formisano,
S. Lo Caputo, A. Saracino

From prevention to cure: ready for new challenges

BARI 14-16 GIUGNO 2023
UNIVERSITA' DEGLI STUDI ALDO MORO



www.icar2023.it

14:30 - 15:30

Auditorium Aldo Moro

>>> Sponsored Symposium

Simposio promozionale di Gilead Sciences

B/F/TAF: your trusted partner also in apparently un-complicated patients

Gilead, a historical company involved in advancing HIV therapy, will host a promotional symposium called "B/F/TAF: Your Trusted Partner also in Apparently Uncomplicated Patients." The symposium will focus on apparently uncomplicated patients in order to better understand their characteristics and raise awareness of the complexity of HIV. Through an analysis of patients' clinical needs, the often-overlooked CNS adverse events, the importance of long-term safety in therapy, and the need to control viral replication for as long as possible, we will draw on the experience of B/F/TAF to present key data on long-term safety and maximal and durable viral suppression, with the aim of identifying the optimal treatment choices for these patients.

Chair: Giulia Carla Marchetti (Milano)

14.30 - 14.35 Introduction

Giulia Carla Marchetti, Milano

14.35 - 14.45 Gilead's commitment in HIV

Frederico da Silva, Milano

14.45 - 15.05 Maximal and durable viral suppression in apparently un-complicated HIV Patients: The role of B/F/TAF

Stefano Bonora, Torino

15.05 - 15.25 The confidence of B/F/TAF Long-Term Safety in HIV Treatment

Giordano Madeddu, Sassari

15.25 - 15.30 Q&A

Giulia Carla Marchetti, Milano

14:30 - 15:30

Aula 4

>>> Expert Meeting

Long-acting antimicrobial experiences in real world patients: toward paradigm change?

The long-acting lipoglycopeptides (LGPs) are antimicrobials with broad and potent activity against Gram-positive bacterial pathogens. While they are approved for acute bacterial skin and soft tissue infections (ABSSSI), their pharmacological properties suggest a potential role of these agents for the treatment of deep-seated and severe infections, such as diabetic foot, bone and joint infections. The use of these antimicrobials is particularly appealing when prolonged therapy, early discharge, and multidrug-resistant bacteria are suspected.

Chairs: Sergio Carbonara (Bari), Anna Maria Cattelan (Padova)



Presidenza del Congresso:
F. Ceccherini Silberstein, M. Formisano,
S. Lo Caputo, A. Saracino

From prevention to cure: ready for new challenges

BARI 14-16 GIUGNO 2023
UNIVERSITA' DEGLI STUDI ALDO MORO



www.icar2023.it

14.30 - 14.45 In the diabetic patient

Francesco Giuseppe De Rosa,
Torino

14.45 - 15.00 In bacterial coinfection

Giustino Parruti, Pescara

15.00 - 15.15 Clinical practice and pharmaco-economic aspects

Rosario Cultrera, Ferrara

15.15 - 15.30 Discussion

14:30 - 15:30

Aula 1

>>> Session

Oral Communications

14:30 - 15:30

Aula 3

>>> Session

Oral Poster

15:35 - 16:35

Auditorium Aldo Moro

>>> Symposium

New issues on antiretroviral drug optimization

With currently available antiretroviral therapy, most people with HIV infection can achieve and maintain HIV viral suppression. Advances in antiretroviral treatment and a better understanding of drug resistance have made it possible to consider switching a person with HIV from an effective regimen to another in defined circumstances. New burning topics including the significance of the archived and resistant HIV, will be discussed

Chairs: Simona Di Giambenedetto (Roma), Giuliano Rizzardini (Milano)



Presidenza del Congresso:
F. Ceccherini Silberstein, M. Formisano,
S. Lo Caputo, A. Saracino

From prevention to cure: ready for new challenges

BARI 14-16 GIUGNO 2023
UNIVERSITA' DEGLI STUDI ALDO MORO



www.icar2023.it

- | | | |
|----------------------|--|----------------------------------|
| 15.35 - 15.50 | Role and impact of drug-resistant and archived HIV | <i>Maurizio Zazzi, Siena</i> |
| 15.50 - 16.05 | How much adherence is necessary to avoid drug-resistance with modern ART 2DRs and 3DRs? | <i>Antonio Di Biagio, Genova</i> |
| 16.05 - 16.35 | Pharmacological interactions: ART and the rest of world | <i>Andrea Calcagno, Torino</i> |

15:35 - 16:35

Aula 6

>>> Satellite Symposium

Con la sponsorizzazione non condizionante di Pfizer

From prevention to cure in SARS-CoV-2: bivalent vaccines and antiviral therapy

COVID-19 places tremendous burden to public health and economy system. The roll-out of COVID-19 vaccines at the beginning of 2021 marked a key turning point in the fight against the global pandemic by limiting disease transmission and progression to death, albeit variable vaccination coverage. Early antiviral treatments can help reduce the risk of serious illness especially in adults at high risk of progressing to severe COVID-19 (as immunocompromised individuals) and may continue to shed virus and remain symptomatic for a longer period.

Chairs: Antonella Cingolani (Roma), Roberto Parrella (Napoli)

- | | | |
|----------------------|--|----------------------------------|
| 15.35 - 15.50 | SARS-CoV-2 early antiviral treatment: in which patients? | <i>Massimo Andreoni, Roma</i> |
| 15.50 - 16.05 | Antiviral therapy in COVID-19 patients | <i>Andrea Antinori, Roma</i> |
| 16.05 - 16.15 | Discussion | |
| 16.15 - 16.30 | SARS-CoV-2 bivalent vaccines efficacy in today's epidemiological scenario | <i>Pier Luigi Lopalco, Lecce</i> |
| 16.30 - 16.35 | Discussion | |

15:35 - 16:35

Aula 4

>>> Session

Oral Communications

Razionale mancante!



Presidenza del Congresso:
F. Ceccherini Silberstein, M. Formisano,
S. Lo Caputo, A. Saracino

From prevention to cure: ready for new challenges

BARI 14-16 GIUGNO 2023
UNIVERSITA' DEGLI STUDI ALDO MORO



www.icar2023.it

15:35 - 16:35

Aula 1

>>> Session

Oral Communications

15:35 - 16:35

Aula 3

>>> Session

Oral Poster

16:40 - 18:00

Auditorium Aldo Moro

>>> Satellite Symposium *Con la sponsorizzazione non condizionante di Gilead Sciences e ViiV Healthcare*

How to manage Heavily Treatment-Experienced patients (HTE)

HTE patients are described as those having two or less antiretroviral (ARV) classes available for use with limited fully active ARV agents within each class. A detailed understanding of the underlying processes that caused previous treatment failures, diagnostics to define resistance, resistance mechanisms and ARV pharmacology should all function in tandem to determine the next steps of clinical care. This Symposium provides an overview of the clinical approach to care, including diagnostics, regimen creation and a broad array of both currently available and upcoming ARVs that may be used in regimens for HTE patients.

Chairs: Franco Maggiolo (Bergamo), Maria Santoro (Roma)

16.40 - 16.55 Who are the HTE patients?

Sergio Lo Caputo, Foggia

New classes of antiretroviral drugs with novel mechanisms of action:

16.55 - 17.10 Fostemsavir, the HIV-1 attachment inhibitor

Stefano Rusconi, Legnano MI



Presidenza del Congresso:
F. Ceccherini Silberstein, M. Formisano,
S. Lo Caputo, A. Saracino

From prevention to cure: ready for new challenges

BARI 14-16 GIUGNO 2023
UNIVERSITA' DEGLI STUDI ALDO MORO



www.icar2023.it

17.10 - 17.25 Lenacapavir, the inhibitor of HIV capsid function

Antonio Di Biagio, Genova

17.25 - 17.40 U=U in HTE patients: myth or reality?

Antonella Castagna, Milano

17.40 - 18.00 Q&A and Panel Discussion

Moderators:

*Franco Maggiolo, Bergamo
Maria Santoro, Roma*

Discussants:

*Antonella Castagna, Milano
Antonio Di Biagio, Genova
Sergio Lo Caputo, Foggia
Stefano Rusconi, Legnano MI*

16:40 - 17:40

Aula 6

>>> Symposium

Immunotherapies in chronic viral infections: What will the future bring?

Immunotherapies, already well established in the management of cancer, are emerging as important tools in the control of chronic viral infections. There are challenges: we need to understand whether stimulating a sluggish immune response, tackling immune inhibition, or directly transferring immune mediators is the best approach; we must carefully consider potential safety liabilities; and we wish for improved biomarkers to optimise patient stratification and monitoring. We will discuss two different scenarios that pose different risk/benefit considerations but are equally challenging. Firstly, we will talk about the initial hopes, subsequent disappointments and current promising approaches that bring us closer to curing chronic HBV infection. A brief case history will then highlight the problem of CMV infection unresponsive to traditional interventions in the setting of transplantation, followed by a lecture on how transfer of CMV-specific T-cells can restore protective antiviral immunity in transplant recipients patients. Come along to this exciting symposium to hear how cutting-edge science is being translated into clinical practice!

Chairs: Nicola Coppola (Napoli), Valentina Svicher (Roma)

16.40 - 17.00 Immunotherapies to cure chronic HBV infection

Carlo Ferrari, Parma

17.00 - 17.05 Case history: the challenge of unresponsive CMV infection in a solid organ transplant recipient

Miriam Lichtner, Latina

17.05 - 17.25 Adoptive immunotherapies for CMV and other viruses in the transplant setting

Patrizia Elisa Comoli, Pavia



Presidenza del Congresso:
F. Ceccherini Silberstein, M. Formisano,
S. Lo Caputo, A. Saracino

From prevention to cure: ready for new challenges

BARI 14-16 GIUGNO 2023
UNIVERSITA' DEGLI STUDI ALDO MORO



www.icar2023.it

17.25 - 17.40 Q&A and Panel Discussion

Discussants:
Patrizia Comoli, Pavia
Nicola Coppola, Napoli
Carlo Ferrari, Parma
Anna Maria Geretti, Roma
Miriam Lichtner, Latina
Massimo Puoti, Milano
Valentina Svicher, Roma

16:40 - 17:40

Aula 4

>>> Session

Oral Communications

16:40 - 17:40

Aula 1

>>> Session

Oral Communications

16:40 - 17:40

Aula 3

>>> Session

Oral Poster

17:45 - 18:45

Aula 6

>>> Session

Oral Communications



Presidenza del Congresso:
F. Ceccherini Silberstein, M. Formisano,
S. Lo Caputo, A. Saracino

From prevention to cure: ready for new challenges

BARI 14-16 GIUGNO 2023
UNIVERSITA' DEGLI STUDI ALDO MORO



www.icar2023.it

17:45 - 18:45

Aula 4

>>> Session

Oral Communications

17:45 - 18:45

Aula 1

>>> Session

Oral Communications

17:45 - 18:45

Aula 3

>>> Session

Oral Poster



venerdì, 16 giugno 2023

09:00 - 10:30

Auditorium Aldo Moro

>>> Lecture

Keynote Lectures

Chairs: Gioacchino Angarano (Bari), Andrea Cossarizza (Modena), Fabrizio Maggi (Roma)

09.00 - 09.30 Mpox 2022: the story of another pandemics

Andrea Antinori, Roma

The main features of the 2022 mpox multi-country outbreak are characterized, in terms of epidemiological issues, peculiarities in sexual transmission, clinical aspects, diagnosis implications, and the course of the disease. Specific characteristics concerning the severity in HIV-infected persons with advanced disease were described, including the virologic compartmentalization, the immunologic signatures, and the complex pathogenesis of mpox in the immunocompromised host. Therapeutic resources based on antivirals and the results of the vaccination campaign, both for immunogenicity and for the impact on the epidemic curve are also reported and discussed.

09.30 - 10.30 COVID-19: virus vs immunocompromised host

*Mario Clerici, Milano
 Carlo Federico Perno, Roma*

Vaccination protocols and the decreased pathogenicity of the new variants of SARS-CoV-2 have changed the face of COVID-19, making it less of a concern. However, there is an exception: in patients with alterations of the immune response, COVID-19 can still be extremely dangerous. The peculiarities of the disease in these particular patients will be analyzed.



10:35 - 11:35

Auditorium Aldo Moro

>>> Sponsored Symposium

Simposio promozionale di ViiV Healthcare

Cabotegravir + Rilpivirine Long-Acting: a new dawn for PLHIV

Long-acting regimens can help people living with HIV to overcome some challenges that have not yet been completely resolved. Today, we are one year from the reimbursement of Cabotegravir + Rilpivirine Long-acting, the first complete long-acting regimen indicated for the treatment of HIV in virologically suppressed patients. The goal of the symposium is to share new scientific evidence supporting the efficacy and safety of CAB+RPV LA, both from clinical trials and local experiences.

Chair: Giuseppe Nunnari (Messina)

10.35 - 10.40 Introduction

Giuseppe Nunnari, Messina

10.40 - 11.00 SOLAR study: the dawn of a new era

Giovanni Di Perri, Torino

11.00 - 11.30 Roundtable: the experience starts with you

*Discussants:
 Nicola Gianotti, Milano
 Cristina Mussini, Modena
 Roberto Rossotti, Milano
 Annalisa Saracino, Bari*

11.30 - 11.35 Take home message

Giuseppe Nunnari, Messina

10:35 - 11:35

Aula 6

>>> Session

Oral Communications



10:35 - 11:35

Aula 1

>>> Expert Meeting

Expert Meeting

Razionale mancante!

10:35 - 11:35

Aula 4

>>> Session

Oral Poster

10:35 - 11:35

Aula 3

>>> Session

Oral Poster

10:35 - 11:35

Aula 2

>>> Parallel Session

U=U: Impossibile Sbagliare

U=U represents the most revolutionary principle and the most effective tool to break down stigma and discrimination against people living with HIV (PLWH) and to improve acceptance of infection and break down self-stigma in PLWH themselves. For this, ICAR's Community Associations constructed a "prospective study to evaluate the impact of a U=U information campaign in two target populations": PLWH and the general population. In this first phase, the construction of the study will be explained and the communication campaign "U=U: Impossible to Be Wrong" will be presented.

Ref. Daniele Calzavara (Milano)



Presidenza del Congresso:
F. Ceccherini Silberstein, M. Formisano,
S. Lo Caputo, A. Saracino

From prevention to cure: ready for new challenges

BARI 14-16 GIUGNO 2023
UNIVERSITA' DEGLI STUDI ALDO MORO



www.icar2023.it

10.35 - 11.35 Presentation of the communication campaign and methodologies of the impact assessment study

11:40 - 12:40

Auditorium Aldo Moro

>>> Symposium

The battle between the virus and the host: an ongoing dynamic process

The symposium is intended to address different topics concerning the delicate balance between protective and pathogenetic role of the immune system over viral infections. In particular, a comprehensive review of the most recent notions on early events (Type-I IFN-s) after HIV and SARS-CoV-2 infection will be provided. The role exerted by host immune factors and ART to contain HIV reservoir will be illustrated as well. The most novel technical approaches to gain exhaustive and more and more detailed information from biological specimens of infected patients will also be thoroughly reviewed during the symposium.

Chairs: Chiara Agrati (Roma), Andrea Gori (Milano)

11.40 - 11.55	Type I Interferon in HIV and SARS-CoV-2 infection: following the mechanistic thread	<i>Carolina Scagnolari, Roma</i>
11.55 - 12.10	Drivers for virus reservoir containment: ART or host immune responses	<i>Andrea De Maria, Genova</i>
12.10 - 12.25	From bed to bench and return: what happens in between?	<i>Sara De Biasi, Modena</i>
12.25 - 12.40	Discussion	

11:40 - 12:40

Aula 6

>>> Special Session

ICAR-CROI Awards 2023

Razionale mancante!

Chairs: Giocchino Angarano (Bari), Francesca Ceccherini Silberstein (Roma), Gabriella d'Ettorre (Roma)



Presidenza del Congresso:
F. Ceccherini Silberstein, M. Formisano,
S. Lo Caputo, A. Saracino

From prevention to cure: ready for new challenges

BARI 14-16 GIUGNO 2023
UNIVERSITA' DEGLI STUDI ALDO MORO



www.icar2023.it

11:40 - 12:40

Aula 1

>>> Session

Oral Communications

11:40 - 12:40

Aula 4

>>> Session

Oral Poster

11:40 - 12:40

Aula 3

>>> Session

Oral Poster

11:40 - 12:40

Aula 2

>>> Parallel Session

Prestigio Meeting

Razionale mancante!

Ref. Castagna



12:45 - 13:45

Auditorium Aldo Moro

>>> Symposium

Clinical COVID-19

The symposium will present virological and clinical paradigms in the prophylaxis and treatment of SARS COV2 infection. In a multidisciplinary approach we will invite a psychiatrist to discuss immune-inflammatory pathways leading to psychopathology and neurocognitive impairment in LongCOVID with a focus on target for treatment. It will end with a round table comparing different models of care in the management of people with LongCOVID highlighting unmet clinical needs and research opportunities.

Chairs: Giovanni Guaraldi (Modena), Loredana Sarmati (Roma)

12.45 - 13.00	Paradigms of a prophylax and early treatment in Covid-19	<i>Massimo Andreoni, Roma</i>
13.00 - 13.15	Psychopathology and neurocognitive impairment in Long COVID: Immunopsychiatry of Long COVID	<i>Francesco Benedetti, Milano</i>
13.15 - 13.45	Round table	
13.15 - 13.25	Introduction Lecture "Challenges in Long-COVID care: Italian experiences and best practices"	<i>Graziano Onder, Milano</i>
13.25 - 13.45	Discussion	<p><i>Moderators:</i> <i>Giulia Carla Marchetti, Milano</i> <i>Marco Falcone, Pisa</i></p> <p><i>Discussants:</i> <i>Massimo Andreoni, Roma</i> <i>Francesco Benedetti, Milano</i> <i>Anna Maria Cattelan, Padova</i> <i>Giovanni Guaraldi, Modena</i> <i>Graziano Onder, Roma</i></p>

12:45 - 13:45

Aula 6

>>> Special Session

Drug pipeline: a glimpse of the future

An open discussion between researchers and R&D representatives of pharmaceutical companies that aims to outline and shape the future of antiviral drug development in the next decade

Chairs: Cristina Mussini (Modena), Carlo Federico Perno (Roma), Stefano Vella (Roma)



Presidenza del Congresso:
F. Ceccherini Silberstein, M. Formisano,
S. Lo Caputo, A. Saracino

From prevention to cure: ready for new challenges

BARI 14-16 GIUGNO 2023
UNIVERSITA' DEGLI STUDI ALDO MORO



www.icar2023.it

12:45 - 13:45

Aula 1

>>> Session

Oral Communications

12:45 - 13:45

Aula 4

>>> Session

Oral Poster

12:45 - 13:45

Aula 3

>>> Session

Oral Poster

12:50 - 14:00

>>> Session

Poster viewing



12:50 - 14:00

Aula 2

>>> Parallel Session

HIV Outcomes in Europe

HIV Outcomes is a European initiative born in 2016, thanks to the support of the members of the European Parliament, bringing together patient organisations, clinicians, academics, public institutions and the private sector to think about a new way of addressing the needs of HIV-positive people, to guarantee that they can live longer, in good health and fully participate in society. HIV Outcomes aims to sensitise policy makers and to implement actions that lead to a patient-centric health system that also includes a change in the clinical approach. Improving the quality of life of people living with HIV means improving the sustainability of European health systems through the sharing of best practices and innovative approaches to care. In 2017 HIV Outcomes presented its 5 Recommendations on the health, well-being and long-term care of people living with HIV to the European Parliament. In 2020, to bring the right attention on HIV of Italian political decision-makers, being at the same time members of the European Parliament, and by healthcare professionals, HIV Outcomes Italia was then created. The ultimate aim is to disseminate the recommendations and vision of HIV Outcomes Europe at national level. In 2022, the Policy Asks, developed together with national initiatives "Enhancing long-term health and well-being among people living with HIV" were presented to the European Parliament.

Chairs: Antonella d'Arminio Monforte (Milano), Mario Cascio (Milano)

12.50 - 13.00	Presentation of the initiative	<i>Antonella d'Arminio Monforte, Milano</i>
13.00 - 13.10	Policy Asks	<i>Mario Cascio, Milano</i>
13.10 - 13.15	The involvement of the Institutions	<i>Sergio Milano, Milano</i>
13.15 - 13.20	The work done, Delphi on Recommendations and initial Institutions engagement	<i>Antonella d'Arminio Monforte, Milano</i>
13.20 - 13.25	Abstract on Surveys on Residential care Homes and Hospitals	<i>Luisa Broganzoli, Milano</i>
13.25 - 13.40	The way forward on Ageing	<i>Antonella d'Arminio Monforte, Milano Mario Cascio, Milano</i>
13.40 - 14.00	Questions and Answers	



14:00 - 15:00

Auditorium Aldo Moro

>>> Symposium

Clinical HIV first! Emerging and re-emerging clinical issues in HIV infection

HIV infection has taken on clinical connotations in the last two decades that are certainly different from what was observed at the beginning of the HIV epidemic. These changes have been induced by the universal use of antiretroviral therapy in our latitudes, although where therapy is not universally available, some clinical pictures may appear different and more similar to what was previously observed. The aim of this symposium is, on the one hand, to bring back the attention especially of young physicians to the classical clinical aspects of HIV infection by focusing on syndromic aspects in different situations of universal availability of ART, especially in terms of late presentation; on the other hand, it is intended to focus attention on particular clinical situations, toward which the availability of new treatments could change the natural history and prognosis of the diseases themselves, such as progressive multifocal leukoencephalopathy and HIV-related neoplasms.

Chairs: Alessandra Bandera (Milano), Giuseppe Nunnari (Messina)

14.00 - 14.20	Syndromic approach to main opportunistic infections in HIV. Focus on limited resources - vs rich resources countries	<i>Carmela Pinnetti, Roma</i>
14.20 - 14.40	Progressive multifocal leukoencephalopathy. Update on diagnostics and therapeutic approaches	<i>Paola Maria Cinque, Milano</i>
14.40 - 15.00	New insights into innovative anti-cancer therapies and their application in HIV-related cancers	<i>Luisa Verga, Monza</i>

14:00 - 15:00

Aula 6

>>> Session

Oral Communications

14:00 - 15:00

Aula 1

>>> Session

Oral Communications



14:00 - 15:00

Aula 4

>>> Session

Oral Poster

14:00 - 15:00

Aula 3

>>> Session

Oral Poster

14:00 - 15:00

Aula 2

>>> Session

Oral Communications

15:05 - 16:05

Auditorium Aldo Moro

>>> Symposium

Chemsex emergency - what happens in real life

Chemsex, or the use of recreational substances during sex, is a widespread practice within the MSM community. Numerous cohort studies on HIV-positive MSM or PrEP users show that the prevalence of the phenomenon is increasing and the substances used are constantly evolving. The chemsex emergency is often spoken of with emphasis on the health and addiction issues related to drug use, but also with a good deal of ignorance leading to stigmatisation of users. The symposium aims to shed light on this practice, providing information on the type of substances most commonly used, the contribution of peer practitioners in the field who, within community associations, offer support to chemsex users, and finally the fundamental role of PrEP in reducing the risk of HIV infection in contexts where other prevention tools would be of doubtful effectiveness.

Chairs: Massimo Cernuschi (Milano), Barbara Suligoj (Roma)



Presidenza del Congresso:
F. Ceccherini Silberstein, M. Formisano,
S. Lo Caputo, A. Saracino

From prevention to cure: ready for new challenges

BARI 14-16 GIUGNO 2023
UNIVERSITA' DEGLI STUDI ALDO MORO



www.icar2023.it

15.05 - 15.20 Old and new psychotropic substances in chemsex practice

Michele Lanza, Milano

15.20 - 15.40 Recreational Chemsex Vs problematic Chemsex

*Filippo Leserri, Roma
Michele Manfredini, Milano*

15.40 - 15.50 Chemsex & PrEP

Silvia Nozza, Milano

15.50 - 16.05 Discussion

15:05 - 16:05

Aula 6

>>> Session

Oral Communications

15:05 - 16:05

Aula 1

>>> Session

Oral Communications

15:05 - 16:05

Aula 4

>>> Session

Oral Poster

15:05 - 16:05

Aula 3

>>> Session

Oral Poster



Presidenza del Congresso:
F. Ceccherini Silberstein, M. Formisano,
S. Lo Caputo, A. Saracino

From prevention to cure: ready for new challenges

BARI 14-16 GIUGNO 2023
UNIVERSITA' DEGLI STUDI ALDO MORO



www.icar2023.it

15:05 - 16:05

Aula 2

>>> Session

Oral Communications

16:05 - 16:30

Auditorium Aldo Moro

>>> Special Session

ICAR 2023 Awards and Closing remarks

Chairs: Francesca Ceccherini Silberstein (Roma), Michele Formisano (Taranto), Sergio Lo Caputo (Foggia), Annalisa Saracino (Bari)

Legenda Acronimi

2DR: two-drug regimen
4DR: four-drug regimen
3TC: lamivudine
ABSSSI: Acute Bacterial Skin and Soft Tissue Infections
AIDS: Acquired Immune Deficiency Syndrome
ANCHOR Study: A randomized study to prevent anal cancer among persons living with HIV
ART: Antiretroviral therapy
ARV: Antiretroviral
APP: Anamnesi Patologica Prossima
AVs: AtrioVentricular Septal
B/F/TAF: bictegravir/emtricitabina/tenofovir alafenamide
CAB: Cabotegravir
CD4: Cluster of Differentiation
CMV: cytomegalovirus
CNS: Central Nervous System
COVID-19: Corona Virus Disease 2019
CROI: Conference on Retroviruses and Opportunistic Infections
DDI: Integrated Differential Diagnosis
DNA: Deoxyribonucleic Acid
DTG: Dolutegravir
ELISA: Enzyme Linked ImmunoSorbent Assay)
EMA: Agenzia Europea per i Medicinali
ET: Early Treatment
FTCI: Fast-Track Cities initiative
HBV: Hepatitis B Virus
HCV: Hepatitis C Virus
HDV: Hepatitis D Virus
HIV: Human Immunodeficiency Virus
HPV: Human Papilloma Virus
HTE: heavily treatment-experienced
ICAR: Italian Conference on AIDS and Retroviruses
ICONA: Italian Cohort of Antiretroviral Naïve Patients.
LA: Long-acting
LGPs: Long-acting lipoglycopeptides
Mabs: Monoclonal Antibodies
MMR: Mismatch repair
MSM: men who have sex with men
NGS: Next generation sequencing
NNRTI: Non-nucleoside Inhibitors
PCR: C-reactive protein
PLWH: People Living With HIV
PrEP: Pre-exposure prophylaxis
PROs: Patient Reported Outcomes
PWH: People with HIV
RCT: Randomized Controlled Trial
R&D: Research and Development

RNA: Ribonucleic Acid

RPV: Rilpivirine

SARS-CoV-2: Severe Acute Respiratory Syndrome Coronavirus-2

SIMIT: Società Italiana di Malattie Infettive e Tropicali

SOLAR: Sequential Oligogenic Linkage Analysis Routines

STIs: Sexually transmitted infections

TGD: Transgender and Gender Diverse

IFN-s: Interferons

U=U: Undetectable = Untransmittable

VOCs: variants of concern

WGS: Whole genome sequencing

Qual. Breve	Cognome	Nome	Laurea	Specializzazione	Qualifica	Divisione	Istituto	Città
Dr.ssa	Agrati	Chiara	Medicina e Chirurgia	Malattie Infettive	Biologo	Malattie Infettive	INMI "Lazzaro Spallanzani" I.R.C.C.S.	Roma
Prof.	Andreoni	Massimo	Medicina e Chirurgia	Malattie Infettive	Direttore - Professore Ordinario Malattie Infettive	U.O.C. di Malattie Infettive	Università degli Studi di Roma "Tor Vergata"	Roma
Prof.	Angarano	Gioacchino	Medicina e Chirurgia	Malattie Infettive	Direttore - Professore	Clinica di Malattie Infettive	Università degli Studi di Bari	Bari
Prof.	Antinori	Andrea	Medicina e Chirurgia	Malattie Infettive	Direttore	U.O.C. Immunodeficienze Virali	INMI "Lazzaro Spallanzani" I.R.C.C.S.	Roma
Prof.	Antonelli	Guido	Medicina e Chirurgia	Malattie Infettive	Professore Ordinario "SSD/MED07 - Microbiologia e Microbiologia Clinica" e Direttore dell'UOC "Microbiologia e Virologia" e del DAI	Dipartimento di Medicina Molecolare - Unità Operativa Complessa di Microbiologia e Virologia - Dipartimento Assistenziale Integrato (DAI) Servizi Diagnostici	AOU (Azienda Ospedaliero-Universitaria) "Policlinico Umberto I"	Roma
Dr.	Armenia	Daniele	Medicina e Chirurgia	Malattie Infettive	Ricercatore/Docente	Clinica di Malattie Infettive	Saint Camillus International University of Health Sciences	Roma
Dr.ssa	Bandera	Alessandra	Medicina e Chirurgia	Malattie Infettive	Dirigente medico, Professore Associato in Malattie Infettive presso l'Università degli Studi di Milano	Divisione di Malattie Infettive	Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico di Milano	Milano
Prof.	Benedetti	Francesco	Medicina e Chirurgia	Psichiatria	Professore Ordinario	Psichiatria	Università Vita-Salute San Raffaele	Milano
Prof.	Bonfanti	Paolo	Medicina e Chirurgia	Malattie Infettive	Professore Associato e Direttore	U.O.C. Malattie Infettive	ASST Monza - Ospedale San Gerardo	Monza

Prof.	Bonora	Stefano	Medicina e Chirurgia	Malattie Infettive	Professore Associato	Dipartimento di Scienze Mediche	Università degli Studi di Torino	Torino
Prof.	Borghi	Claudio	Medicina e Chirurgia	Medicina Interna	Professore Ordinario	Clinica Medica generale e Terapia" e "Medicina di emergenza e Urgenza	Università degli Studi di Bologna	Bologna
Dott.ssa	Brogonzoli	Luisa	Economia Aziendale	//	Responsabile	Centro Studi	Fondazione The Bridge	Milano
Dr.	Calcagno	Andrea	Medicina e Chirurgia	Malattie Infettive	Medico	Clinica Universitaria di Malattie Infettive	Azienda Sanitaria Locale "Città di Torino" Regione Piemonte - Ospedale Amedeo di Savoia	Torino
Dr.ssa	Callegaro	Annapaola	Medicina e Chirurgia	Medicina legale e delle assicurazioni	Dirigente Medico	Unità Operativa Microbiologia e Virologia	ASST Papa Giovanni XXIII	Bergamo
Sig.ra	Calvino	Giulia Valeria	//	//	Vicepresidente	//	ANLAIDS	Roma
Dr.	Calzavara	Daniele	//	//	Coordinate	//	Associazione Milano Check Point	Milano
Dr.ssa	Caraglia	Anna	Medicina e Chirurgia	Statistica Sanitaria indirizzo Programmazione socio sanitaria	Dirigente Medico	Direzione Generale della Prevenzione Sanitaria - Ufficio 1 - Affari generali e segreteria tecnico-organizzativa	Ministero della Salute	Roma
Dr.	Carbonara	Sergio	Medicina e Chirurgia	Malattie Infettive	Direttore	U.O.C. Malattie Infettive	AOU Consorziata - Policlinico Giovanni XXIII	Bari
Dott.	Cascio	Mario	//	//	Attivista	HIV	NPS (Network Persone Sieropositive) Italia ONLUS	Milano
Prof.ssa	Castagna	Antonella	Medicina e Chirurgia	Malattie Infettive	Professore Associato - Dirigente Medico	Divisione di Malattie Infettive - Palazzina B – Centro San Luigi – 3° piano	IRCCS Ospedale San Raffaele Università Vita-Salute	Milano
Dr.ssa	Cattelan	Anna Maria	Medicina e Chirurgia	Malattie Infettive	Direttore	U.O.C. Malattie Infettive e Tropicali	Azienda Ospedaliera di Padova	Padova

Dr.	Cavallari	Eugenio Nelson	Medicina e Chirurgia	Malattie Infettive	Dirigente Medico I livello	Dipartimento Malattie Infettive e Tropicali	Università degli Studi Di Roma La Sapienza	Roma
Prof.ssa	Ceccherini - Silberstein	Francesca	Chimica e Tecnologie Farmaceutiche	Biologia	Professore Associato di Virologia	Laboratorio di Virologia - Facoltà di Medicina e Chirurgia	Università degli Studi di Roma "Tor Vergata"	Roma
Dr.	Celesia	Benedetto Maurizio	Medicina e Chirurgia	Malattie Infettive	Dirigente Medico I livello	Istituto Malattie Infettive	ARNAS Garibaldi - P.O. Nesima	Catania
Dr.	Cernuschi	Massimo Giuseppe Luigi	Medicina e Chirurgia	Malattie Infettive	Dirigente Medico	Clinica di Malattie Infettive - Day Hospital	Ospedale San Raffaele	Milano
Dr.ssa	Cicalini	Stefania	Medicina e Chirurgia	Malattie Infettive	Dirigente Medico I Livello	UOC Immunodeficienz e virali e Neuro oncologia infettiva	INMI Lazzaro Spallanzani IRCCS	Roma
Dr.ssa	Cingolani	Antonella	Medicina e Chirurgia	Malattie Infettive	Dirigente Medico	Istituto di Clinica delle Malattie Infettive	IRCCS Fondazione Policlinico Universitario Agostino Gemelli	Roma
Dr.ssa	Cinque	Paola Maria	Medicina e Chirurgia	Malattie Infettive	Dirigente Medico	Divisione di Malattie Infettive	IRCCS Ospedale San Raffaele	Milano
Prof.	Clerici	Mario Salvatore	Medicina e Chirurgia	Medicina Interna	Direttore	Dipartimento di Fisiopatologia Medico-Chirurgica e Trapianti	Università degli Studi di Milano	Milano
Dr.ssa	Comoli	Patrizia Elisa	Medicina e Chirurgia	Pediatria	Dirigente Medico I Livello	Dip. Materno-infantile: Oncoematologia Pediatrica	Fondazione IRCCS Policlinico San Matteo	Pavia

Dr.	Conversano	Michele	Medicina e Chirurgia	Igiene, epidemiologia e sanità pubblica	Direttore	Dipartimento di prevenzione	ASL Taranto	Taranto
Prof.	Coppola	Nicola	Medicina e Chirurgia	Malattie Infettive	Direttore Unità Complessa Epatiti Virali Professore Ordinario di Malattie Infettive Seconda Università di Napoli	Malattie Infettive	Azienda Ospedaliera Università della Campania Luigi Vanvitelli	Napoli
Prof.	Cossarizza	Andrea	Medicina e Chirurgia	Patologia clinica	Professore ordinario	Cattedra di Patologia Generale e Immunologia	Università di Modena e Reggio Emilia	Modena
Prof.ssa	d'Arminio Monforte	Antonella	Medicina e Chirurgia	Malattie Infettive	Direttore - Professore Ordinario di Malattie Infettive	Clinica di Malattie Infettive e Tropicali - Dipartimento di Scienze della Salute	ASST Santi Paolo e Carlo - Polo Universitario	Milano
Dr.ssa	d'Ettore	Gabriella	Medicina e Chirurgia	Malattie Infettive	Dirigente Medico	I divisione Malattie Infettive	Azienda Policlinico Umberto I	Roma
Dr.	Da Silvia	Frederico	Scienze Farmaceutiche	Marketing Management	General Manager	HIV	Gilead	Milano
Dr.ssa	De Biasi	Sara	Medicina e Chirurgia	Malattie Infettive	Ricercatore	U.O.C. di Malattie Infettive	Università di Modena e Reggio Emilia	Modena

Prof.	De Maria	Andrea	Medicina e Chirurgia	Malattie Infettive	Responsabile UOS Immunologia delle Malattie Infettive	Clinica di Malattie Infettive	Policlinico San Martino IRCCS, Università degli Studi di Genova	Genova
Prof.	De Rosa	Francesco Giuseppe	Medicina e Chirurgia	Malattie Infettive	Prof. Associato - Responsabile Clinica di Malattie Infettive II dell'Università di Torino, con sede all'Ospedale di Asti	Clinica Malattie Infettive	AOU Città della Scienza e della Salute	Torino
Dr.ssa	Degasperi	Elisabetta	Medicina e Chirurgia	Gastroenterologia	Dirigente Medico I livello	S. C. Gastroenterologia ed Epatologia	Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico	Milano
Prof.	Di Biagio	Antonio	Medicina e Chirurgia	Malattie Infettive	Ricercatore a tempo determinato e Professore a contratto	Dipartimento di scienze della salute	Ospedale Policlinico S.Martino, IRCCS, Università degli Studi di Genova	Genova
Dr.	Di Gennaro	Francesco	Medicina e Chirurgia	Malattie Infettive	Dirigente Medico I livello	UOC Clinica Universitaria Malattie Infettive	AOU Consorziale - Policlinico Giovanni XXIII	Bari
Dr.ssa	Di Giambenedetto	Simona	Medicina e Chirurgia	Malattie Infettive	Ricercatore Universitario	Clinica malattie infettive	Università Cattolica del Sacro Cuore	Roma
Prof.	Di Perri	Giovanni	Medicina e Chirurgia	Malattie Infettive	Direttore	Clinica Universitaria di Malattie Infettive	Ospedale Amedeo di Savoia, Università degli Studi di Torino	Torino
Prof.	Falcone	Marco	Medicina e Chirurgia	Medicina Interna	Professore Associato	Dipartimento di Medicina clinica e sperimentale	Università di Pisa	Pisa

Prof.	Ferrari	Carlo	Medicina e Chirurgia	Malattie Infettive	Dirigente Medico II livello	Malattie Infettive ed Epatologia	Azienda Ospedaliero-Universitaria di Parma	Parma
Sig.	Formisano	Michele	//	//	Presidente NPS Puglia Onlus e Vice Presidente NPS Italia Onlus	//	NPS (Network Persone Sieropositive) Italia ONLUS	Taranto
Dr.ssa	Gagliardini	Roberta	Medicina e Chirurgia	Malattie Infettive	Dirigente Medico II livello	U.O.C. Immunodeficienz e Virali e Neuro-Oncologia Infettiva	INMI "Lazzaro Spallanzani" I.R.C.C.S.	Roma
Prof.ssa	Gainty	Caitjan	Bioetica e diritto della salute	Dottorato di ricerca nella storia	Professore	Storia della Scienza, della Medicina e della Tecnologia	King's College	London
Prof.	Galli	Massimo	Medicina e Chirurgia	Malattie Infettive	Professore Ordinario - Direttore Malattie Infettive III	Dipartimento di Scienze Biomediche e Cliniche "L. Sacco"	ASST Fatebenefratelli Sacco - Ospedale Luigi Sacco, Università degli Studi di Milano	Milano
Prof.	Gentile	Ivan	Medicina e Chirurgia	Malattie Infettive	Professore	Malattie Infettive	AOU Policlinico "Federico II" - Università degli Studi	Napoli
Prof.ssa	Geretti	Anna Maria	Medicina e Chirurgia	Malattie Infettive	Professoressa Virologia	Department of Clinical Infection - Microbiology and Immunology	Policlinico Tor Vergata	Roma
Dr.ssa	Gervasoni	Cristina	Medicina e Chirurgia	Malattie Infettive	Dirigente Medico	III Divisione Malattie Infettive	ASST Fatebenefratelli Sacco	Milano

Prof.	Gianfrilli	Daniele	Medicina e Chirurgia	Endocrinologia	Professore Associato	Dipartimento di Medicina Sperimentale - Sez. di Fisiopatologia Medica ed Endocrinologia	“Sapienza” Università di Roma - Azienda Ospedaliero-Universitaria Policlinico Umberto I	Roma
Dr.	Gianotti	Nicola	Medicina e Chirurgia	Malattie Infettive	Medico	Unità Operativa di Malattie Infettive - Centro San Luigi	IRCCS San Raffaele, Università Vita-Salute	Milano
Prof.	Gori	Andrea	Medicina e Chirurgia	Malattie Infettive	Direttore	Divisione di Malattie Infettive	Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico	Milano
Prof.	Guaraldi	Giovanni	Medicina e Chirurgia	Malattie Infettive e tropicali	Medico Ricercatore	Clinica di Malattie Infettive e tropicali	Università degli studi di Modena e Reggio Emilia - UNIMORE	Modena
Dr.	Iachetta	Roberto Paolo	Medicina e Chirurgia	Chirurgia Generale	Dirigente Medico I livello	Unità Operativa Complessa Chirurgia Proctologica	Ospedale di Sassuolo	Sassuolo (MO)
Prof.	Ippolito	Giuseppe	Medicina e Chirurgia	Malattie Infettive	Direttore Generale	Ricerca e Innovazione	Ministero della Salute	Roma
Dr.	Lanza	Michele	Farmacia	//	Responsabile di progetto	Progetto Chemsex	ASA - Associazione Solidarietà AIDS	Milano
Dr.	Lapadula	Giuseppe	Medicina e Chirurgia	Malattie Infettive	Dirigente Medico I livello	Unità Operativa di Malattie Infettive	Azienda Ospedaliera San Gerardo	Monza
Prof.	Lazzarin	Adriano	Medicina e Chirurgia	Malattie Infettive	Direttore	Divisione di Malattie Infettive - Palazzina B – Centro San Luigi – 3° piano	IRCCS San Raffaele, Università Vita-Salute	Milano
Dr.	Leserri	Filippo	//	//	Vicepresidente	//	Plus aps Roma	Roma
Prof.ssa	Lichtner	Miriam	Medicina e Chirurgia	Malattie Infettive	Professore associato e Direttore	UOC Malattie Infettive	Ospedale Regionale Santa Maria Goretti	Latina

Prof.	Lo Caputo	Sergio	Medicina e Chirurgia	Malattie Infettive	Professore Associato di Malattie Infettive	Dipartimento di medicina clinica sperimentale - Clinica Malattie infettive	AOU Ospedali Riuniti, Università di Foggia	Foggia
Dr.ssa	Lombardi	Francesca	Biologo	Biologo	Biologo	Unità Operativa di Malattie Infettive	IRCCS Fondazione Policlinico Universitario A. Gemelli	Roma
Prof.	Lopalco	Pier Luigi	Medicina e Chirurgia	Malattie Infettive	Professore	Dipartimento di Malattie Infettive	Università del Salento	Lecce
Prof.	Madeddu	Giordano	Medicina e Chirurgia	Malattie Infettive	Professore Associato e Dirigente Medico	Malattie Infettive Dipartimento di Medicina Clinica e Sperimentale	Azienda Ospedaliero Universitaria di Sassari	Sassari
Prof.	Maggi	Fabrizio	Medicina e Chirurgia	Microbiologia e Virologia	Professore Associato	Dipartimento di Medicina e Chirurgia	Università degli Studi dell'Insubria	Varese
Prof.	Maggi	Paolo	Medicina e Chirurgia	Malattie Infettive	Direttore	U.O.C. Malattie Infettive e Tropicali	A.O. Sant'Anna e San Sebastiano	Caserta
Dr.	Maggiolo	Franco	Medicina e Chirurgia	Malattie Infettive	Dirigente Medico	Struttura Complessa Malattie Infettive	ASST Papa Giovanni XXIII	Bergamo
Sig.	Manfredini	Michele	//	//	coordinatore	gruppo monosintomatico o terapeutico sul Chemsex	ASA Associazione Solidarietà AIDS Onlus	Milano
Prof.ssa	Marchetti	Giulia Carla	Medicina e Chirurgia	Malattie Infettive	Dirigente medico	Clinica delle Malattie Infettive -Dipartimento di Medicina, Chirurgia ed Odontoiatria	Università degli Studi di Milano - ASST Santi Paolo e Carlo	Milano

Prof.	Mastroianni	Claudio Maria	Medicina e Chirurgia	Malattie Infettive	Professore Ordinario	Unità Operativa Complessa Malattie Infettive	Policlinico Umberto I - Sapienza Università di Roma	Roma
Dr.ssa	Mazzotta	Valentina	Medicina e Chirurgia	Malattie Infettive	Medico	UOC Immunodeficienze e virali	INMI Lazzaro Spallanzani	Roma
Dr.	Meli	Davide	//	//	Attivista	//	Bergamo Fast Track City	Bergamo
Dr.	Meli	Paolo	Psicopedagogia	//	Psicopedagogo	C.I.C.A. - Coordinamento Italiano delle Case Alloggio per persone con HIV/AIDS	Associazione Comunità Emmaus	Bergamo
Dr.ssa	Mercurio	Ilaria	//	//	Attivista	//	Croce Rossa Italiana Comitato di Bergamo Rete Fast Track City	Bergamo
Dr.ssa	Micheli	Valeria	Scienze Biologiche	Microbiologia e Virologia	Dirigente Biologo	U.O. di Microbiologia e Virologia	ASST Fatebenefratelli Sacco - Ospedale Luigi Sacco	Milano
Dr.	Milano	Sergio	//	//	Attivista	HIV	NPS (Network Persone Sieropositive) Italia ONLUS	Milano
Prof.	Mosca	Davide	Medicina e Chirurgia	Malattie Infettive	Professore Associato	Dipartimento di salute della migrazione	Institute for Global Health, University College London	Londra
Dr.	Moschese	Davide	Medicina e Chirurgia	Malattie Infettive e Tropicali	Dirigente Medico I livello	Unità Operativa di Malattie Infettive	Ospedale Luigi Sacco - Polo Universitario	Milano

Prof.ssa	Mussini	Cristina	Medicina e Chirurgia	Malattie Infettive	Direttore e Professore Associato	Clinica di Malattie Infettive e Tropicali - Ingresso 31 - Piano Terra	Azienda Ospedaliero-Universitaria Policlinico di Modena	Modena
Dr.	Nicastri	Emanuele	Medicina e Chirurgia	Malattie Infettive	Dirigente Medico II livello - Direttore	UOC Divisione di Malattie Infettive ad Alta Intensità di Cura e Altamente Contagiose	INMI "Lazzaro Spallanzani" I.R.C.C.S.	Roma
Dr.ssa	Nozza	Silvia	Medicina e Chirurgia	Malattie Infettive	Dirigente medico	Divisione di Malattie Infettive	IRCCS San Raffaele	Milano
Prof.	Nunnari	Giuseppe	Medicina e Chirurgia	Malattie Infettive	Direttore	UOC Malattie Infettive	Azienda Ospedaliera Universitaria Policlinico "G. Martino"	Messina
Prof.	Onder	Graziano	Medicina e Chirurgia	Geriatría	Professore Ordinario	Dipartimento di Scienze geriatriche e ortopediche	Università Cattolica del Sacro Cuore	Milano
Dr.	Orofino	Giancarlo	Medicina e Chirurgia	Malattie Infettive	Dirigente Medico I livello	U.O. di Malattie Infettive e Tropicali I	Ospedale Amedeo di Savoia - ASL TO2 Torino	Torino
Dr.	Parrella	Roberto	Medicina e Chirurgia	Malattie Infettive	Dirigente Medico I livello	Unità Operativa di Malattie Infettive	Azienda Ospedaliera Specialistica dei Colli - Ospedale Cotugno	Napoli
Dr.	Parruti	Giustino	Medicina e Chirurgia	Malattie Infettive	Direttore	Unità Operativa Complessa di Malattie Infettive	Ospedale Civile Santo Spirito - ASL Pescara	Pescara
Sig..	Patrucco	Stefano	//	//	Segretario	Sezione Infettivologia	Associazione Arcobaleno Aids Torino	Torino
Prof.	Perno	Carlo Federico	Medicina e Chirurgia	Oncologia	Direttore	Microbiologia e Diagnostica di Immunologia Padiglione Salvati - Piano 1	IRCCS Ospedale Pediatrico Bambino Gesù, Roma Gianicolo	Roma
Dr.ssa	Pinnetti	Carmela	Medicina e Chirurgia	Malattie Infettive	Medico	Malattie Infettive	INMI "Lazzaro Spallanzani" I.R.C.C.S.	Roma

Prof.	Puoti	Massimo	Medicina e Chirurgia	Malattie Infettive	Direttore S.C. Malattie Infettive	Struttura Complessa Malattie Infettive	ASST Grande Ospedale Metropolitano Niguarda	Milano
Dr.ssa	Rancilio	Laura Amelia Rachele	Medicina e Chirurgia	Pediatria	Medico	Pediatria Malattie Infettive	Caritas Ambrosiana	Milano
Dr.	Ridolfi	Marco	Medicina e Chirurgia	Malattie Infettive	Dirigente Medico I livello	Unità Operativa di Malattie Infettive	Università Degli Studi Di Roma La Sapienza	Roma
Dr.	Rizzardini	Giuliano	Medicina e Chirurgia	Malattie Infettive	Direttore - Dirigente Medico II livello	Dipartimento di Malattie Infettive I	ASST Fatebenefratelli Sacco	Milano
Dr.	Rossotti	Roberto	Medicina e Chirurgia	Malattie Infettive	Dirigente Medico	SC Malattie Infettive	ASST Grande Ospedale Metropolitano Niguarda	Milano
Prof.	Rusconi	Stefano	Medicina e Chirurgia	Malattie Infettive	Professore associato di Malattie Infettive e Direttore UO	Dipartimento di Scienze Biomediche e Cliniche "Luigi Sacco"	Ospedale Civile di Legnano - ASST Ovest Milanese	Legnano (MI)
Dr.	Saladini	Francesco	Biotecnologie per la salute umana	Microbiologia e Virologia	Ricercatore Universitario	Dipartimento di Biotecnologie Mediche - 5° blocco rosa	A.O.U. Senese - Ospedale Santa Maria alle Scotte	Siena
Prof.ssa	Santantonio	Teresa Antonia	Medicina e Chirurgia	Malattie Infettive	Professore Associato	Unità Operativa Complessa Malattie Infettive	Università degli Studi di Foggia - Ospedali Riuniti	Foggia
Prof.ssa	Santoro	Maria	Scienze Biologiche	Immunobiologia Medica	Biologo ricercatore	Dipartimento di Medicina Sperimentale	Università degli Studi di Roma "Tor Vergata"	Roma
Dr.	Saracini	Luca	Medicina e Chirurgia	Malattie Infettive	Dirigente Medico II livello	Assistenza e accoglienza per persone in HIV/Aids	C.I.C.A. Opere Caritative Francescane	Ancona
Prof.ssa	Saracino	Annalisa	Medicina e Chirurgia	Malattie Infettive	Professore Associato e Dirigente Medico	Struttura Complessa di Malattie Infettive	AOU Consorziale - Policlinico Giovanni XXIII	Bari
Prof.ssa	Sarmati	Loredana	Medicina e Chirurgia	Malattie Infettive	Professore Associato	Unità Operativa Complessa	Dipartimento di Medicina dei Sistemi, Università Tor Vergata Roma	Roma

Prof.ssa	Scagnolari	Carolina	Medicina e Chirurgia	Malattie Infettive	Professore Associato	Dip. Medicina Molecolare - Lab. Virologia	Università La Sapienza	Roma
Dr.	Schloesser	Filippo	Scienze Politiche	//	Presidente	//	Nadir	Roma
Dr.	Squillace	Nicola	Medicina e Chirurgia	Malattie Infettive	Dirigente Medico II livello	Unità Operativa Complessa di Malattie Infettive	UOC Malattie Infettive Fondazione IRCCS San Gerardo dei Tintori	Monza
Dr.ssa	Suligoi	Barbara	Medicina e Chirurgia	Gastroenterologia ed endoscopia digestiva	Direttore	Centro Operativo AIDS	Istituto Superiore di Sanità	Roma
Dr.ssa	Svicher	Valentina	Medicina e Chirurgia	Malattie Infettive	Professore Associato	Cattedra di Virologia	Fondazione PTV - Policlinico Tor Vergata	Roma
Dr.ssa	Taibi	Chiara	Medicina e Chirurgia	Malattie Infettive	Dirigente Medico I livello	Unità Operativa Complessa di Malattie Infettive	INMI "Lazzaro Spallanzani" I.R.C.C.S.	Roma
Prof.	Torti	Carlo	Medicina e Chirurgia	Malattie Infettive	Direttore	U.O. Malattie Infettive	Università degli Studi "Magna Græcia" di Catanzaro	Catanzaro
Prof.ssa	Turriziani	Ombretta	Scienze biologiche	Microbiologia e virologia	Biologo	Virologia	Università La Sapienza	Roma
Prof.	Vella	Stefano	Medicina e Chirurgia	Malattie Infettive	Adjunct Professor	Global Health	Università Cattolica del Sacro Cuore	Roma
Dr.ssa	Venturelli	Serena	Medicina e Chirurgia	Malattie Infettive	Dirigente Medico I livello	U.S.C. Malattie Infettive	ASST Papa Giovanni XXIII	Bergamo
Dr.ssa	Verga	Luisa	Medicina e Chirurgia	Ematologia	Dirigente Medico I livello	Unità Operativa di Ematologia	Azienda Ospedaliera San Gerardo	Monza
Dr.ssa	Vichi	Francesca	Medicina e Chirurgia	Malattie Infettive	Medico chirurgo	Malattie Infettive	Ospedale Santa Maria Annunziata - ASL 10	Bagno a Ripoli
Prof.	Zazzi	Maurizio	Scienze Biologiche	Microbiologia e virologia	Professore Associato di Microbiologia	Dipartimento di Biotecnologie Mediche - 5° blocco rosa	A.O.U. Senese - Ospedale Santa Maria alle Scotte	Siena